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ABSTRACT  
 
Hypertension is the most common cardiovascular diseases suffered by geriatric patients. Their 
physiological changes make the administration of conventional tablets less effective, especially 
regarding compliance. One approach to overcome this problem is the development of orodispersible 
tablets, which soften easily and disintegrate quickly in the oral cavity. Atenolol is a class of β-blocker 
functioning as an anti-hypertensive drug that has been extensively used in hypertension therapy, and it 
has the potential to being developed as orodispersible tablets. A faster disintegration of orodispersible 
tablets will facilitate an earlier onset of dissolution. The addition of superdisintegrants can reduce the 
disintegration time of these tablets. Croscarmellose sodium is a superdisintegrant that can decrease the 
disintegration time to less than three minutes. This study aimed to optimize the formula of 
orodispersible tablets of atenolol using different concentrations of croscarmellose sodium, namely 
10% (formula 1) and 20% (formula 2). The physicochemical characteristics of the tablets were 
evaluated to determine the best formula. The evaluation included a comparison to the control formula 
(0% of croscarmellose sodium). The results showed that formula 1 (10% of croscarmellose sodium) 
produced orodispersible tablets with the best physicochemical characteristics regarding tablet 
hardness, friability, in vitro dispersion time, and disintegration time. Formula 1 (%Q30 minutes= 98.31%) 
also met the standard of the dissolution of atenolol tablets set by the Farmakope Indonesia, i.e., the 
percent of dissolved drug in 30 minutes has to be higher than 85%. The drug dissolution efficiency of 
formula 1 was twice higher than that of the control formula.  
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INTRODUCTION 
Hypertension is one of the degenerative diseases suffered by geriatric patients. It is a 
cardiovascular disease with increased prevalence in older adults (Dipiro et al., 2008). Atenolol is a β-
blocker (β1-selective) antihypertensive drug that is widely used for the treatment of all lines of 
hypertension, angina pectoris, arrhythmias, and myocardial infarction (Dipiro et al., 2008). It is also an 
antihypertensive drug listed in the formulary of the Social Security Administering Agency (BPJS 
Indonesia) of Health. In oral administration, it is absorbed by approximately 50%, and most of the 
absorbed doses reach the systemic circulation. The half-life of atenolol is 6-7 hours with tmax between 
2-4 hours (Sweetman, 2009). Atenolol is a compound with low water solubility and dissolution but 
high permeability (Khirwadkar and Dashora, 2013). The low water solubility results in a slow 
dissolution process that affects the onset of drug action and atenolol bioavailability in the systemic 
circulation. The conventional administration of atenolol tablets with a glass of water causes discomfort 
to geriatric patients as they experience physiological changes, such as difficulty in swallowing and 
chewing, tremor, and risk of choking (Khirwadkar and Dashora, 2013).  
The development of atenolol as orodispersible tablets is an approach to reduce the time required 
for tablet disintegration and minimize the problems in the conventional administration of tablets, 
especially in geriatric patients. Orodispersible tablet or orally disintegrating tablet (ODT) is a dosage 
form that quickly dissolves into fine particles when placed in the oral cavity (European Pharmacopoeia 
Commission, 2005). It can be absorbed in the mouth, pharynx, and esophagus and dissolved and 
dispersed in saliva in less than three minutes (European Pharmacopoeia Commission, 2005). 
Furthermore, ODT has several advantages, including fast dissolution process and drug action, 
minimum first-pass effect, and increased drug bioavailability (Chandrasekhar et al., 2013). It also 
facilitates patients in taking medicine and, thereby, increases their drug compliance because (1) it is 
easily swallowed and effective, (2) it has a relatively good flavor, and (3) patients do not need to chew 
and drink it with water (Kumare et al., 2013). Therefore, this research developed the formulation of 
atenolol for orodispersible tablets.  
An essential component in the formulation of orodispersible tablets as a dosage form is 
disintegrant. Selecting a suitable disintegrant is, therefore, necessary mainly to create ODT formulas 
that meet the required physicochemical characteristics. The use and the selection of disintegrants have 
to be precise in order to obtain the desired dissolution and disintegration rates (Sulaiman, 2007; 
Camarco et al., 2006). Disintegrant is one of the additional ingredients in drug formulation that serves 
to break the tablet into smaller particles, enabling fast dissolution process. A group of disintegrant 
used in low level in the preparation of tablets is termed superdisintegrant. It is considered to be 
effective as an excipient in ODTs when applied with concentrations between 10% and 20% (Hahm 
and Augsburger, 2008). One type of superdisintegrant that can be used in ODT formulation is 
croscarmellose sodium. (Hahm and Augsburger, 2008). Croscarmellose sodium facilitates the 
disintegration process through the mechanism of swelling, recovery of elastic energy, and capillary 
action (wicking). It is a fiber-like polymer with a rather short size and adequate flow characteristics. Its 
long fiber-shaped structure can widen the distance between the constitutive particles of the matrix 
tablet, which accelerates the disintegration process (Hahm and Augsburger, 2008). Accordingly, a 
thorough study related to the effects of croscarmellose sodium concentration in the ODT formula on 
the physicochemical characteristics of the produced ODT.  
This research formulated orodispersible tablets of atenolol with croscarmellose sodium as 
superdisintegrant at different concentrations, namely 10% (formula 1) and 20% (formula 2). It also 
used a control formula, i.e., an orodispersible tablet of atenolol prepared without the addition of 
croscarmellose sodium (0%). The formulation stage included pre-compression and post-compression 
evaluations. The results of this stage determined the most favorable formula based on the physical 
characteristics of ODT and the dissolution of atenolol. The addition of different concentrations of 
croscarmellose sodium as a disintegrant was analyzed for its impact on the physicochemical 
characteristics of ODT, i.e., disintegration time, dispersion time, tablet hardness, and atenolol level. 
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Furthermore, the pharmaceutically qualified formulas with the best physical properties were tested for 
their dissolution rate according to the standards issued in the Farmakope Indonesia V (Depkes RI, 
2014).  
  
MATERIALS AND METHODS 
Materials 
The materials used in this study included pharmaceutical components, excipients, and reagents. 
All of the components and excipients were pharmaceutical grade. The components were atenolol, 
mannitol DC (direct compress), croscarmellose sodium, Avicel PH 102®, magnesium stearate, 
Aerosil®, aspartame, and talc. The reagents and other chemicals included methanol (Merck), sodium 
dihydrogen phosphate (Merck), disodium hydrogen phosphate (Merck), sodium acetate (Merck), and 
glacial acetic acid (Merck). All of the reagents and chemicals were analytical grades. 
 
Preparation of the pressed mass 
The composition of the ingredients used in the pressed mass is presented in Table I. This study 
used three formulas for the production of orodispersible tablets of atenolol with croscarmellose sodium 
as superdisintegrant. The formulas included a control (0%), formula 1 (10% of croscarmellose 
sodium), and formula 2 (20% of croscarmellose sodium). The pressed mass of each formula was 
prepared by initially mixing atenolol with some of Aerosil® for 3 minutes and then with some of the 
Avicel PH 102® for 5 minutes. The next step was the addition of croscarmellose sodium as the 
superdisintegrant with different concentrations according to the formulas (0%, 10%, or 20%), 
aspartame, mint flavor, the rest of the Avicel PH 102®, and mannitol DC. These components were 
mixed in a tumbling mixer until homogeneous for 10 minutes. This process produced the powder form 
of the orodispersible tablets before compression.  
 
Table I. The formulas of the orodispersible tablets of atenolol with croscarmellose sodium 
at concentrations of 0% (control), 10% (formula 1), and 20% (formula 2) 
 
Ingredients Control 
Formula 
(mg) 
Formula 1 
(mg) 
Formula 2 
(mg) 
Atenolol 25 25 25 
Croscarmellose sodium - 30 60 
Aspartame 9 9 9 
Mg Stearate 4.5 4.5 4.5 
Aerosil 1.5 1.5 1.5 
Talc  3 3 3 
Mint Flavor 3 3 3 
Mannitol DC 50.8 44.8 38.8 
Avicel PH 102
®
 203.2 179.2 155.2 
Total weight per tablet  300 300 300 
 
Pre-compression evaluation 
After the powder form of the orodispersible tablets was created, a pre-compression evaluation 
was performed. It analyzed the flow rate, angle of repose, compressibility index, Hausner ratio, and 
moisture content of the powder.  
 
Flow rate and angle of repose  
The flow rate and angle of repose were identified by weighing 100 grams of the powder form. 
This powder was poured into a funnel set on a stative, and the distance between the lower end of the 
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pipe to the flat plane was 10.0±0.2 cm. The lower hole of the funnel was closed. This hole was then 
opened later, and the time required for the material to flow out of the funnel was recorded with a 
stopwatch for flow rate calculation. The next step was measuring the height of the material pile and the 
radius of the cone base, as well as calculating the resultant angle of repose (Aulton  and Summers, 
2013). 
 
Compressibility index 
The compressibility index of the powder form was determined by measuring two types of bulk 
density, namely freely settled bulk density and tapped bulk density of the powder form (Aulton and 
Summers, 2013). Both data were used to calculate the compressibility index of the powder using the 
following equation: 
 
                      
     
  
      
 
where: 
ρT  : freely settled bulk density of the powder  
ρB : tapped bulk density of the powder 
 
Hausner ratio 
Hausner ratio compares the tapped bulk density with the freely settled bulk density of the 
powder (Aulton, 2013). Both Hausner ratio and compressibility index were used to predict the 
flowability of the powder.  
 
Moisture content  
The moisture content was measured by weighing 5 grams of the powder form. The surface of the 
powder was flattened on the container. The position of the heating lamp was arranged in a way that it 
was above the material. During the drying process, the weight of the powder was displayed every 15 
minutes.  
A drying process is deemed perfect when the weight of the powder does not change for 3x15 
minutes (Aulton & Summers, 2013). Moisture content was calculated using the following formula: 
    
    
  
      
where: 
MC  : moisture content 
W  : wet weight of the powder 
W0 : dry weight of the powder 
 
Compression of orodispersible tablets of atenolol 
Before the compression process from a powder into a tablet dosage form, the powder was mixed 
first with the external phase, i.e., magnesium stearate, talc, and the remaining Aerosil® using a 
tumbling mixer for three minutes until homogeneous. This powder mixture was then compacted into a 
tablet dose using ERWEKA® AR 402 tablet compression machine, and the weight of each tablet was 
300 mg. The diameter of the punch was 11 mm, the surface of the punch was round and biconvex, and 
the compression force was 2 tons.  
 
Post-compression evaluation 
After the powder form was pressed into a tablet dose, a post-compression assessment was 
performed. Aside from organoleptic analysis, the evaluated properties were atenolol content, hardness, 
disintegration time, tablet dispersion time, friability, and dissolution.  
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Organoleptic analysis 
This analysis was conducted by observing the physical appearance of every tablet produced by 
each formula, including the odor, color, flavor, and shape of the compressed orodispersible tablets of 
atenolol.  
 
Identification of atenolol content 
The atenolol levels were assessed by sampling 20 tablets of each formula randomly. The twenty 
samples were crushed together. A mixture of atenolol that was equivalent to 25 mg was weighed and 
dissolved with 10 mL of methanol in a measuring flask, then added with acetate buffer solution (pH 
4.6) up to 100 mL. Ten mL of this solution was transferred with a pipet into a measuring flask and 
added with acetate buffer solution up to 25 mL. This solution was filtered with Whatman paper No.41. 
The absorbance of the filtered solution was measured with UV-VIS spectrophotometer at a wavelength 
of 274 nm using an acetate buffer blank (pH 4.6) (Chandrasekhar et al., 2013). 
 
Evaluation of tablet hardness 
The tablet hardness was evaluated using the instrument ‘Monsanto hardness tester’. The number 
of samples collected from each formula for this evaluation was ten tablets.  
 
Disintegration time test 
Disintegration time is a critical parameter to observe in the evaluation of orodispersible tablets. 
The disintegration time was tested by placing 6 tablets (of each formula) into 6 different tubes 
containing 900 mL of water with a temperature of 37±0.5
0
C. As the test apparatus started, the 
stopwatch was turned on. The length of time that the tablet required to disintegrate, or the duration that 
the core mass needed to become palpable, was determined as the disintegration time of the tablet 
(Chandrasekhar et al., 2013; Kumare et al., 2013). 
 
In vitro dispersion time test 
Each tablet from the three formulas was placed in a beaker containing 6 mL of phosphate buffer 
solution (pH 6.8) with a temperature of 37±0.5
0
C. The time required by the tablet to crumble was 
recorded as the in vitro dispersion time (Chandrasekhar et al., 2013; Kumare et al., 2013). 
 
Friability and abrasion tests 
The friability and abrasion tests were performed by selecting several tablets until a weight of 6.5 
gram was reached, i.e., approximately 22 tablets (for tablets weighing lower than 650 mg). These 
tablets were weighed using an analytical balance. Afterward, they were placed into the friability and 
abrasion tests instrument, which was operated at 25 rpm for 4 minutes. The weight of the entire tablets 
was recorded, and the weight difference between the tablets before and after the test was calculated 
(Chandrasekhar et al., 2013; Aulton  and Summers, 2013). The percentage of friability or abrasion was 
calculated using the following formula:  
 
            
                         
            
      
 
Dissolution test  
The dissolution test of the orodispersible tablets of atenolol was performed on a dissolution 
media, i.e., 900 mL of 0.1 N acetic acid buffer (pH 4.6), according to the standardized procedure 
issued in Farmakope Indonesia V (Depkes RI, 2014). The dissolution test apparatus used the type 2 
(paddle) at 50 rpm. The first step was inserting six tablets of each formula into the apparatus. Then, 10 
mL of samples was drawn every time of observation, namely 0, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 45, 60, 
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75, 90, 105, and 120 min. Afterward, 10 mL of 0.1 N acetic acid (pH 4.)6 was returned to the 
apparatus. The next step was assessing the atenolol level of each sample using a spectrophotometer at 
a wavelength of 274 nm. The dissolution parameter (% Q, tQ%, the area under the dissolution curve 
(AUC), and dissolution efficiency) and dissolution profile were identified based on the readings 
(Chandrasekhar  et  al., 2013). The dissolution of AUC was determined by calculating the area formed 
under the dissolution profile. Dissolution efficiency was defined as the area under the dissolution 
curve until a certain time limit and expressed as a percentage of the rectangle are depicted by 100% 
dissolution at the same time limit (Khan, 1975).   
 
Data Analysis 
The post-compression evaluation results of the orodispersible tablets of atenolol created with the 
control formula (0% of croscarmellose sodium), formula 1 (10% of croscarmellose sodium), and 
formula 2 (20% of croscarmellose sodium) were statistically analyzed using One-way ANOVA with 
95% confidence level (α= 0.05). The examined parameters included disintegration time and in vitro 
dispersion time. The AUC dissolution and dissolution efficiency of the selected formula were 
compared with the control formula using a pooled t-test.  
 
RESULTS AND DISCUSSION 
The orodispersible tablets of atenolol in this research were prepared using croscarmellose 
sodium as superdisintegrant. The formula designed in this study aimed to determine the effects of 
different concentrations of croscarmellose sodium on the physicochemical characteristics of the 
resulted tablets. A control formula was designed without superdisintegrant. Meanwhile, formula 1 and 
formula 2 used 10% and 20% of croscarmellose sodium, respectively. The pre-compression evaluation 
was performed on the powder form of these three formulas. It included flow rate, angle of repose, 
compressibility index, Hausner ratio, and moisture content. The results of the pre-compression 
evaluation are presented in Table II. 
 
Table II. The results of the pre-compression evaluation of the orodispersible tablets of atenolol 
with different concentrations of croscarmellose sodium (0%, 10%, and 20%) 
 
Parameters Formulas* Standards 
Control 
(0%) 
Formula 1 
(10%) 
Formula 2 
(20%) 
Flow rate (g/s) 9.31±0.16 7.10±0.82 7.38±0.31 4-10 
Angle of repose (°) 32.15±0.00 27.84±01.35 29.53±0.29 5°-35° 
Compressibility (%) 23.69±0.499 25.48±1.07 27.55±0.36 < 25% 
Hausner Ratio 1.32±0.006 1.34±0.02 1.38±0.01 < 1.25 
Moisture content (%) 4.80±0.234 5.11±0.15 5.28±0.56 3-5% 
*The figures represent the average values 
  
The flow rates of the three formulas were between the range of 4-10 g/s, indicating sufficient 
flow characteristics (Hahm  and Augsburger, 2008; Aulton  and Summers, 2013). The angle of repose 
was employed in this study to characterize the flow of a solid particle as it served as an indicator of 
interparticle friction or movement resistance between particles (United States Pharmacopeia 
Convention, 2017). Based on the angle of repose, both formula 1 and formula 2 had an excellent flow 
characteristic, whereas the control formula was categorized as a powder with sufficient flow.  
The assessment of compressibility index and Hausner ratio aimed to identify the characteristics 
of the powder form during tableting. The threshold for good powder compressibility is smaller than 
20% (Agoes, 2012). The Hausner ratio can be divided into three groups, namely excellent flow (1.00-
1.11), good flow (1.12-1.18), and sufficient flow (1.19-1.25). The results of both compressibility index 
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and Hausner ratio categorized the control formula and formula 1 as a passable powder or, in other 
words, a powder could flow. On the contrary, formula 2 was concluded as a category of powder with 
poor flow. Based on the angle of repose, Hausner Ratio, and compressibility index, the powder form 
had a good flow with some obstacles. The poor Hausner ratio and compressibility index were caused 
by the presence of a large number of fine particles in the powder (Aulton and Summers, 2013). The 
moisture contents of control formula, formula 1, and formula 2 were 4.80%, 5.11%, and 5.28%, 
respectively. The presence of hygroscopic excipient caused such high moisture content. The 
superdisintegrant used in this research had a high affinity for water so that the powder absorbed 
moisture from the air (Aulton  and Summers, 2013). The moisture content of a powder form has to be 
controlled to prevent sticking or picking on the punch during the tablet compression process. 
The post-compression evaluation in this study included organoleptic examination and tests of 
atenolol level, tablet hardness, disintegration time, in vitro dispersion time, friability, abrasion, and 
dissolution. The results are summarized in Table III. The organoleptic characteristics of control 
formula, formula 1, and formula 2 were round, white, sweet flavor, and minty odor. The physical 
appearance of the orodispersible tablets of atenolol produced in this study is presented in Figure I.  
The atenolol contents in control formula, formula 1, and formula 2 met the thresholds set by the 
Farmakope Indonesia, namely 90%-110% (Depkes RI, 2014). The orodispersible tablets of atenolol 
must have sufficient physical strength to withstand various mechanical shocks during the 
manufacturing, packaging, and delivery processes. The orodispersible tablets of atenolol produced in 
this research had an excellent hardness between the range of 2-4 kg (Deshmukh et al., 2012; Sharma, 
2013). The three formulas met the standards for ODT hardness.  
 
 
 
Figure 1. The orodispersible tablet of atenolol with croscarmellose sodium as superdisintegrant  
 
 Table III. The results of the post-compression evaluation of the orodispersible tablets of 
atenolol with different concentrations of croscarmellose sodium (0%, 10%, and 
20%)  
 
Parameters Formulas* Standards 
Control 
(0%) 
Formula 1 
(10%) 
Formula 2 
(20%) 
Organoleptic Round, white, 
sweet flavor, 
minty odor 
Round, white, 
sweet flavor, 
minty odor 
Round, white, 
sweet flavor, 
minty odor 
Round, white, 
sweet flavor, 
minty odor 
Atenolol level (%) 93.99±0.13 109.10±0.13 108.51±0.22 90.0-110.0% 
Hardness (kP) 2.85±0.24 3.15±0.58 2.90±0.21 2-4 Kp 
Disintegration time 
(s) 
4.00±0.00 2.57±0.00 2.89±0.00 < 3 minutes  
In vitro dispersion 
time 
15.00±0.00 4.44±0.41 7.29±0.56 
 
- 
Friability (%) 0.20±0.09 0.07±0.03 0.17±0.08 < 1% 
Abrasion (%) 0.25±0.18 0.07±0.02 0.07±0.02 < 1% 
*The figures represent the average values 
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This research also evaluated the disintegration time and the in vitro dispersion time of the 
produced tablets. Favorable disintegration time for orodispersible tablets of atenolol is less than 3 
minutes (≤180 seconds) (European Pharmacopoeia Commission, 2005). All of the three formulas met 
the standards of tablet disintegration time in the purified water. Formula 1, containing 10% of 
croscarmellose sodium, had the shortest disintegration time. In vitro dispersion time predicts the 
ability of an orodispersible tablet to break into fine particles with a very limited volume of saliva (± 6 
ml). The statistical analysis, i.e., One-way ANOVA, showed that there was a significant difference of 
disintegration time between the three formulas (p <0.05). Furthermore, the results of the post hoc 
Tukey test showed that the dispersion time of formula 1 (10% of croscarmellose sodium) was faster 
than the other formulas. A rapid dispersion time indicates that the tablet is immediately dispersed into 
fine particles when in contact with saliva in the oral cavity (Nagendrakumar et al., 2010). Based on the 
evaluation of the physical characteristics, formula 1 (10% of croscarmellose sodium) produced 
relatively fast disintegration time compared to control formula and formula 2. Increased concentration 
of croscarmellose sodium from 10% to 20% caused both disintegration time and in vitro dispersion 
time become longer because this superdisintegrant expanded when in contact with aqueous media. 
This condition triggers the formation of viscous barrier on the tablet surface, inhibiting the penetration 
of water into the tablet (Desai et al., 2014). 
Based on the physical properties, formula 1 (10% of croscarmellose sodium) is the best formula 
regarding pre-compression and post-compression characteristics (disintegration time and in vitro 
dispersion time). Therefore, the dissolution properties of formula 1 were identified, and the results 
were compared with the dissolution of the control formula. The dissolution profiles of formula 1 and 
the control formula are depicted in Figure 2, while the calculation results of the dissolution parameters 
of both formulas are summarized in Table IV.  
 
 
Figure 2. The dissolution profiles of orodispersible tablets of atenolol produced with control 
formula (0% of croscarmellose sodium) and formula 1 (10% of croscarmellose 
sodium) 
 
 
 
 
 
 
 
Pharmaciana ISSN: 2088 4559; e-ISSN: 2477 0256  
 
The effects of …(Parfati and Rani) 
 
 
 
 
95 
Table IV. The dissolution parameters of the orodispersible tablets of atenolol 
produced with the control formula and formula 1 
 
Dissolution Parameters Control Formula Formula 1 
AUC 5,190.32±2.78 10,964.99±27.99 
Dissolution efficiency 
(ED120 minutes (%)) 
43.25±0.02 91.37±0.23 
%Q (30 minutes) 53.85 98.31% 
tQ% (minutes) 270.84 1.91 
K dissolution 0.1893/minute 0.4150/minute 
 
Based on the unpaired t-test, the AUC values and dissolution efficiencies of formula 1 and the 
control formula are different (p <0.05). The dissolution efficiency of formula 1 (10% of 
croscarmellose sodium) is twice higher than the control formula. Furthermore, the orodispersible 
tablets of atenolol prepared using formula 1 met the requirements of ODT dissolution. The amount of 
dissolved atenolol (formula 1) in 30 minutes was 98.31%, which is higher than the standard set by the 
Farmakope Indonesia, i.e., 85% (Depkes RI, 2014).  
 
CONCLUSIONS  
In this study, the different concentrations of croscarmellose sodium as superdisintegrants in the 
formulation of orodispersible tablets of atenolol affect the physicochemical properties of the ODT. 
Orodispersible tablets of atenolol prepared with 10% of croscarmellose sodium (formula 1) exhibit 
optimum results in both pre-compression and post-compression evaluations. This formula successfully 
produces ODT of atenolol with the fastest disintegration time and the highest dissolution compared to 
the other formulas.  
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